Background: Autologous hematopoietic stem cell transplantation (HSCT) is a second line treatment for severe refractory Crohn's disease (CD) patients. We evaluated feasibility and toxicity of autologous HSCT for refractory CD. Methods: In this prospective study, refractory CD patients with an aggressive course despite medical treatment, impaired quality of life and no surgical options were included. Hematopoietic stem cells were mobilized (cyclophosphamide and granulocyte colony-stimulating factor) and collected by leukapheresis from peripheral blood. In a second step, a nonmyeloablative conditioning regimen with cyclophosphamide and rabbit antithymocite globulin (rATG) was used and previously collected stem cells were infused. Toxicity and complications during mobilization and conditioning phases and first-year follow up were evaluated. Results: Twenty-six patients were included. Infectious complications during mobilization included 16 febrile neutropenias, 1 bacteriemia, and 2 bacteriemias associated with septic shock (2 of 3 isolated microorganisms were multi-drug resistant bacteria). Neutropenia median time was 5 days and hospitalization median time was 18 days. Five patients did not continue to the second phase of the study: leukapheresis was not successful in 2 patients, 1 patient withdrew the study after mobilization, another one required surgery and the fifth one reached clinical remission after mobilization, so 21 patients entered into the conditioning phase. Hospitalization median time was 26 days, hematopoiesis recovery median time for neutrophils (>1×10 9 /L) was 12 days and for platelets (>20×10 9 /L) 4 days. Red cell transfusion was required in all patients. For infectious complications, 95% of patients presented febrile neutropenia, 8 Gram-positive coccus were isolated, 2 Gram-negative bacilli were identified after neutrophil recovery and 3 patients presented worsening of perianal CD activity. Among non-infectious complications, 6 patients suffered rATG reaction, 12 mucositis and 2 hemorrhagic complications. Infectious complications during the study prompted us to revise and intensify supportive measures as well as to introduce new empirical antibiotic schedules. During the first 12-month follow up, viral infections were the most common and in one patient, cytomegalovirus led to multiorganic failure and death. Conclusions: Autologous HSCT for refractory CD patients is feasible if extraordinary supportive measures are applied. We consider that this procedure should only be developed in highexperienced centers applying the same security measures than those used for allogeneic transplantation.
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Head-to-head comparison of 5 fecal markers to predict response to induction and maintenance therapy with infliximab in ulcerative colitis patients; a prospective study Background: The role of faecal markers in monitoring anti TNF alpha therapies has been insufficiently explored. This study aimed to determine the usefulness of five faecal proteins in the prediction of clinical response to Infliximab (IFX) in Ulcerative Colitis (UC): calprotectin (fCal), Lactoferrin (fLac), M2-PK (fM2-PK), neopterin (fNeo), and zonulin (fZo). Methods: Thirty-one consecutive patients with an active UC, requiring IFX [5 mg/kg at week 0 (W0), 2, 6 and every 8 W] were prospectively studied. At W0, W2, W6 and W14, clinical activity was recorded and a stool sample collected. Clinical response to induction therapy was defined at W14 as a reduction of at least 3 points and 30% of the Mayo score. In 25 patients, endoscopies were performed at W0 and W12; an endoscopic Mayo subscore of 0 or 1 defined endoscopic remission. Clinical response to maintenance therapy was evaluated at W52 and optimization or discontinuation of IFX were considered as a failure. Results: At W0 the median partial Mayo Score, the endoscopic Mayo and the UCEIS scores were 7/9 (2 9), 3/3 (2 3) and 8/11 (6 11) respectively. At W14, 19 patients (61%) were clinical responders and 13 (52%) experienced an endoscopic response. The median levels of fCal drop dramatically from W0 to W14 in responders [from 4260 mg/g (96 25051) to 128 mg/g (11 3782); p = 0.0001]. In contrast, it did not differ significantly in non-responders [from 9077 mg/g (215 50000) to 2781 mg/g (203 14149); p = 0.287]. Same trends were observed for fLac and fM2-PK levels. At W2, fLac and fM2-PK predicted accurately clinical response to IFX induction [area under the curve (AUC) = 0.82, 0.84 and 0.88 respectively]: cuts-offs of 800 mg/g for fCal, 20000 ng/g for fLac and 50 UI/mL for fM2-PK determined by ROC curves allowed to discriminate clinical responders from non responders to induction therapy, with good sensitivities (Se) (82%, 81% and 88%, respectively), and specificities (Sp) (69%, 70% and 80%, respectively). FLac measured at W2 were the more valuable marker to predict endoscopic remission at W12 (AUC=0.80, Se and Sp=72% with a cut-off of 32891 ng/g). At W14, the three previous markers were also reliable to predict clinical response at W52 (AUC=0.82, 0.86 and 0.75 respectively) with best cut-offs of 146 mg/g for fCal, 3457 ng/g for fLac and 2.25 UI/mL for fM2-PK. FCal, fLac and fM2-PK were well correlated with both the endoscopic Mayo subscore and the UCEIS. FNeo and fZo did not show any relevant result. Conclusions: FCal, flac and fM2-PK predicted with a good accuracy the clinical response to induction and maintenance IFX therapy in UC. The measurement of one of these markers at W0 and at the end of induction might distinguish responders S264 Poster presentations from non responders to IFX maintenance therapy within one year. Background: Mucosal healing, based on histological analysis, is an endpoint of maintenance therapy for patients with ulcerative colitis (UC). There are few data on how histological signs of inflammation develop under treatment with Infliximab (IFX). We investigated the patterns of histological features of inflammation in patients with UC in sustained clinical and endoscopic remission under IFX. Methods: We performed a retrospective study on 47 patients with UC in clinical and endoscopic remission and undergoing surveillance colonoscopy with biopsies while receiving maintenance therapy with IFX. Each colonic segment was evaluated based on the Mayo endoscopic subscore and the Geboes histology score (range, 0 to 5.4). Results: Globally, 6110 biopsy specimens were collected from 235 colonoscopies. At the beginning of the follow-up, histological features of inflammation were found in 48.9% of patients receiving maintenance IFX therapy; 25.9% of them had at least moderate inflammation based on histology scores. At the end of the follow-up, when patients were still under endoscopic and clinical remission, 40.4% of patients had at least one biopsy specimen with evidence of any histological inflammation during the follow-up, and 19.1% had biopsy specimens that met the Geboes criteria for abnormal histological inflammation (Figure 1 ). In none of the different disease locations (pancolitis, left-sided colitis, distal colitis) histological inflammation improved significantly during the follow-up. 
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Gut microbiota in patients with inflammatory bowel disease and irritable bowel syndrome before and after 6 weeks of low FODMAP diet N. Methods: Fecal samples were collected from IBD IBS patients in remission having irritable bowel symptoms (ROME III criteria) and randomized (not blinded) to a LFD or a normal (Western/Danish) diet (ND) during 6 weeks. IBS severity score (IBS-SSS) was scored by patients at week 0 and week 6 on an eHealth web-application, www.ibs.constant-care.dk. Bacterial DNA analysis was performed with the GA-map IBS Dysbiosis semi-quantitative Test (Genetic Analysis AS, Oslo, Norway). This 16S rRNA based test utilizes DNA probes designed to facilitate separation between patient groups and normal subjects based on their bacterial gut composition, the most common gut bacteria are represented. A numeric representation of the deviation, a "Dysbiosis Index" (DI), is calculated and change in DI between a baseline and a follow-up sample is also investigated in this work. Results: A total of 50 IBD IBS patients (median 41 years, range 20 69), 39 (78%) females: 15 (30%) CD and 35 (70%) UC were included in the study. 24 (48%) were in LFD and 26 (52%) in ND. At baseline, 35 (70%) had dysbiosis, 10 (20%) had normal biosis and 5 (10%) had inconclusive result. At week 6, 25 (50%) had dysbiosis, 10 (20%) had normal biosis and 10 (20%) uncertain. 5 (10%) patients had missing dysbiosis data. Overall there was no significant difference in dysbiosis index (DI) changes at baseline versus week 6 (median 8.5, range 2.5 104) vs. (median 6.0, range 1.9 121), p = 0.18. In LFD/normal diet group, 18 (75%)/17 (75%) had dysbiosis, 4 (17%)/3 (12%) had normal biosis and 2 (8%)/6 (23%) had inconclusive result at baseline. There was no significant difference in DI changes at baseline comparing to week 6 in both LFD/ND group [in median (range)] [12.6 (3.1 97.2)/ 7.4 (2.5 105) vs. 7.3 (1.9 121)/4.6 (2.2 105), p = 0.68/0.07]. Furthermore, no significant difference in DI in the LFD group compared to the ND group (p = 0.17) after 6 weeks treatment was observed. A significant improvement in IBS-SSS total score in all patients was observed (mean 210, range 60 454) at week 0, compared to (mean 117, range 0 368) week 6, p < 0.01. Conclusions: High proportions (70%) of the IBD IBS patients were dysbiotic at baseline and 50% at week 6. There was not found significant changes in the microbiota in IBD IBS patients after 6 weeks in LFD group compared to ND.
